ZHAOKE OPHTH-B (06622) announced its interim results with a net loss of approximately 123 million yuan, an increase of 5.12% year-on-year.
Zhaoke Ophthalmology-B (06622) announced its interim results for 2026, with revenue of 18.828 million yuan, a year-on-year increase of 19.14%; a net loss of approximately 123 million yuan, a year-on-year increase of 5.12%; and a loss per share of 0.22 yuan.
ZHAOKE OPHTH-B (06622) announced its mid-term results for 2026, with revenue of 18.828 million yuan, a year-on-year increase of 19.14%; net loss of approximately 123 million yuan, a year-on-year increase of 5.12%; and a loss per share of 0.22 yuan.
The announcement stated that the increase in losses was mainly due to a decrease in interest income from bank deposits, reflecting the global rate cuts since mid-2025, as well as an increase in expenses recognized for equity-settled share-based payments included in general and administrative expenses.
Related Articles

BBMG (02009) subsidiary obtains real estate project.

FDB HOLDINGS (01826) released its interim results, with a shareholder loss of HK$10.348 million, a year-on-year increase of 100.4%.

LANDSEA LIFE (01965) released its interim results, with profit attributable to shareholders reaching HK$ 5.618 million, an increase of 230.28% year-on-year.
BBMG (02009) subsidiary obtains real estate project.

FDB HOLDINGS (01826) released its interim results, with a shareholder loss of HK$10.348 million, a year-on-year increase of 100.4%.

LANDSEA LIFE (01965) released its interim results, with profit attributable to shareholders reaching HK$ 5.618 million, an increase of 230.28% year-on-year.

RECOMMEND





